SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction (SHIELD)

Publication date: May 14, 2026

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Concepts Keywords
Breastfeeding Adults
Herpesvirus Combination
Methamphetamine Covid
Stable Criteria
Surgery Disorder
Investigator
Long
Months
Opinion
Paxlovid
Screening
Shield
Urine
Valacyclovir
Visit

Semantics

Type Source Name
disease MESH Long COVID
drug DRUGBANK Valaciclovir
drug DRUGBANK Celecoxib
drug DRUGBANK Metamfetamine
drug DRUGBANK Cocaine
drug DRUGBANK Phencyclidine
disease MESH psychiatric disorder
disease MESH anxiety
disease MESH obsessive-compulsive disorder
disease MESH alcohol use disorder
disease MESH substance use disorder
drug DRUGBANK Medical Cannabis
disease MESH bipolar disorder
disease MESH schizophrenia
disease MESH schizoaffective disorder
disease MESH cardiac
disease MESH hepatitis
disease MESH bacterial infection
drug DRUGBANK Prednisone
drug DRUGBANK Warfarin
drug DRUGBANK Heparin
drug DRUGBANK Digoxin
drug DRUGBANK Amiodarone
drug DRUGBANK Isoniazid
drug DRUGBANK Phenytoin
drug DRUGBANK Fluconazole
drug DRUGBANK Methotrexate
drug DRUGBANK Probenecid
drug DRUGBANK Raloxifene
disease MESH sleep apnea
disease MESH weight loss
disease MESH IBS
disease MESH colonic inertia

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *